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Abstract
Background: Devices currently used to achieve hemostasis of the femoral artery following percuta-
neous cardiac catheterization are associated with vascular complications and remnants of artificial 
materials are retained at the puncture site. The Secure arterial closure Device induces hemostasis by 
utilizing thermal energy, which causes collagen shrinking and swelling. In comparison to established 
devices, it has the advantage of leaving no foreign material in the body following closing. This study 
was designed to evaluate the efficacy and safety of the Secure Device to close the puncture site following 
percutaneous cardiac catheterization.
Methods: The Secure Device was evaluated in a prospective non-randomized single-center trial with 
patients undergoing 6 F invasive cardiac procedures. A total of 67 patients were enrolled and the device 
was utilized in 63 patients. Fifty diagnostic and 13 interventional cases were evaluated. Femoral artery 
puncture closure was performed immediately after completion of the procedure. Time to hemostasis 
(TTH), time to ambulation (TTA) and data regarding short-term and 30-day clinical follow-up were 
recorded. 
Results: Mean TTH was 4:30 ± 2:15 min in the overall observational group. A subpopulation of 
patients receiving anticoagulants had a TTH of 4:53 ± 1:43 min. There were two access site compli-
cations (hematoma > 5 cm). No major adverse events were identified during hospitalization or at the  
30 day follow-up.
Conclusions: The new Secure Device demonstrates that it is feasible in diagnostic and interventional 
cardiac catheterization. With respect to safety, the Secure Device was non-inferior to other closure devices 
as tested in the ISAR closure trial. (Cardiol J 2019; 26, 3: 233–240)
Key words: catheterization, vascular closure device, thermal vascular occlusion, Secure 
Device System, femoral vascular access
Introduction
Interventional cardiology has become a leader 
in both diagnosing and treating coronary artery 
disease. Although radial access seems to be fa-
voured in acute coronary syndrome, femoral access 
is commonly used worldwide in both acute and 
chronic settings.
Following catheterization, the standard proce-
dure for closing the common arteria femoralis is 
mechanic compression to achieve hemostasis. Ap-
plying pressure to the puncture site and prolonging 
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the time to mobilization leads to discomfort for the 
patient and promotes side effects of immobilization. 
Furthermore, manual compression in combination 
with compression devices usage is associated with 
increased personnel requirements and consider-
able financial burden for health care institutions [1].
Hemostatic devices are categorized as being 
pressure devices, hemostatic pads or active vas-
cular closure devices. Currently available active 
closure devices are divided into three groups: col-
lagen plugs, suture based devices and plugs/clips. 
Clips are most frequently made of bio-resorbable 
materials or metal applied to both the inner and/ 
/or outer layer of the arterial wall [2, 3].
Generally, the majority of closure devices 
leave foreign materials either inside or outside the 
blood vessel, which are either permanently left in 
place or gradually dissolve over time. Objects that 
are left inside the body could potentially lead to the 
development of limb ischemia, occlude an artery, be 
a source of infection or disable re-puncture at the 
same site for months. Taking these potential ad-
verse effects into consideration, a vascular closure 
device that achieves hemostasis without requiring 
any components to be left in the patient’s body 
would be desirable. The principle of thermal ves-
sel occlusion is currently under investigation [4].
The secure arterial closure device was develo-
ped to enable hemostasis using thermal energy to 
achieve vessel occlusion without leaving any foreign 
materials inside the patient. A clinical study was 
conducted in Georgia on 42 patients, using an earlier 
version of the device. The earlier version of the de-
vice was Conformité Européenne approved and used 
in Germany on 50 patients. Clinical data regarding 
performance and safety have not yet been published.
The hypothesis was that the Secure Device 
System is non-inferior in terms of vascular ac-
cess site complication to other vascular closure 
devices [5].
Methods
The study was a prospective single center 
single group study designed to evaluate the safety 
and performance of the Secure Device (Model: 
SE-HE-A2) powered by an external power supply. 
The study was performed from September 2016 
to January 2017 after receiving approval from 
the Austrian Federal Office of Safety and Health 
Care (BASG). All procedures and investigations 
were accomplished in accordance to the Declara-
tion of Helsinki and approved by the local ethics 
committee (ref. no: 28-364 ex15/16). Written 
informed consent was obtained from every indi-
vidual participating. 
The patients included were undergoing either 
coronary angiography and/or coronary interven-
tion procedures using 6 French sheaths. Detailed 
inclusion and exclusion criteria are shown in the 
Supplementary materials. An angiogram was 
performed at the access site to evaluate puncture 
location and artery morphology. Puncture loca-
tions above the femoral bifurcation were defined 
as feasible for the Secure Device occlusion (Fig. 1) 
and only arteries with a diameter above 6 mm and 
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Figure 1. X-ray examination of patient prior to Secure arterial closure Device implantation; puncture site location 
control; red arrow — 6 F sheath; white arrow — common femoral artery.
an artery depth greater than 10 mm to the surface 
of the skin were accepted for inclusion. Exclusion 
criteria included heavy calcification visualized at 
the angiogram or a medical history of obstructive 
peripheral artery disease. 
Eighty-two individuals were screened during 
the study procedures and 67 subjects were enrolled 
in the clinical trial after final intra-procedural inclu-
sion (Fig. 2). 
The system included an artery locator, a di-
lator and the Secure Device itself (Fig. 3). After 
finishing the procedure, the artery locator was 
introduced via the sheath with the help of the 
deployer at the proximal end. After successful 
introduction, the deployer was disconnected and 
removed. The sheath can be withdrawn while 
the deployed artery locator remains within the 
artery. To enlarge the tissue canal, the dilator 
was “screwed” in until the green mark was vis-
ible behind the dilator at the artery locator shaft. 
After removing the dilator, the Secure Device was 
inserted and advanced until the green indicator 
was visible on the same level as the alignment 
mark on the device to ensure optimal positioning 
of the heating dome (Fig. 4). Gentle permanent 
tension at the artery locator seals the hole in the 
artery during closing procedure. A stabilization 
slider at the base of the Secure Device ensured 
the correct pressure was applied.
The heating process was activated manually 
by pressing the activation button on the handle. 
A built-in test monitored the device while it was 
being activated. While the heating process was 
occurring, the artery locater was automatically 
un-deployed and retracted into the Secure Device 
handle. The heating process was regularly termi-
nated within 5 to 7 s. Arterial closure LED light and 
vibration signal indicated the end of the procedure. 
After being rotated 90 degrees’, the Secure Device 
and the artery locater were easily removed from 
the patient. Minimal oozing from subcutaneous 
vessels may have occurred. Light compression was 
performed to prevent local subcutaneous bleeding 
on an as needed basis. 
Time to hemostasis (TTH) was determined 
as the time between Secure Device removal and 
observed hemostasis in minutes and seconds. 
Device malfunctions were recorded and ana-
lysed regarding their relation to safety. Device 
malfunction included device related malfunction 
due to indicated inactivity or premature stopping 
of the heating process as well as mechanical 
obstacles and user errors using the device. The 
primary readout for this study was vascular ac-
cess site complications. These complications 
included palpable hematoma measuring at least 
5 cm in size, pseudo aneurysms, arteriovenous 
fistula formation, major bleeding related to the 
access site, acute leg ischemia, the need for 
vascular surgical or interventional treatment and 
local infections at 30 days after the procedure. 
Adverse events not previously described were 
investigated. Time to ambulation (TTA) was 
measured as the time from the Secure Device 
being removed from the patient to the subjects 
being able to walk at least 10 m. 
Follow up of the patients took place at 4 time 
points: 2–4 h after Secure Device use, at ambula-
tion, prior to discharge and a final examination 
30 days after the procedure.
Statistical analysis
All parameters are expressed as mean ±stand-
ard deviation of the mean, as number of patient 
counts or percentage. TTH (primary endpoint) and 
TTA are expressed as mean ± standard deviation 
of the mean, as minutes (TTH) or hours (TTA). 
The statistical analysis of the complication rate 
was designed to reject the null hypothesis that 
the Secure Device is inferior in terms of vascular 
access-site complications to vascular closure de-
vices (FemoSeal and Exoseal) as described in the 
ISAR-CLOSURE trial [5]. 
The ISAR-CLOSURE trial reported a compli-
cation rate of 6.9% in patients that were treated 
with a vascular closure devices. This was consid-
ered to be the null-hypothesis proportion for this 
trial. As in the ISAR-CLOSURE trial, considering 
that the majority of expected complications are 
not severe in nature, a non-inferiority margin that 
represents 140% of the null-hypothesis proportion 
was chosen, which results in a 3% margin of non-
inferiority. The expected complication rate for the 
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82 patients
screened
67 patients
enrolled
51 patients time to
hemostasis evaluation
4 patients excluded
(user error device not activated)
11 patients compression
device applied
1 patients haematoma prior
to device activation
63 patients secure
device system
activated
Figure 2. Flowchart of patients included in the trial.
Figure 4. A. Artery locator insertion and deploying the artery locator in the vessel; removing the sheath over the artery 
locator shaft; B. Pre-dilating the tissue tract; C. Inserting the Secure arterial closure Device to the alignment mark; 
D. Activate the Secure arterial closure Device to close the vessel.
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Figure 3. Secure Device including artery locator, dilator and the Secure artery closure Device. The external battery 
pack is not sterile and reusable. The tip of the artery locator with the deploying unit is made of nitinol and is covered 
by an elastic membrane made by PolyBlend (Advan Source biomaterials, Wilmington, MA). The shaft of the artery 
locator, made of Polyether Ether Ketone, served as a guide for the secure device. The dilator is made of a high-density 
plastic and should be inserted at an angle of approximately 45° to the artery. The tip of the Secure Device is 4.5 mm in 
diameter and made of silicone coated silver plated copper. A plastic wire protruded 1–2 mm from the stainless-steel 
tube at the end of the locator, indicating a fully deployed artery locator tip.
A B
C D
Secure Device was estimated to be at most 5%. 
Given a type I error rate of a = 5%, a power of 80%, 
a null-hypothesis proportion of 6.9%, an expected 
true proportion of 5%, and a non-inferiority margin 
of 3%, the necessary sample size was determined 
to be 123 subjects. 
However, the study was terminated early 
as the manufacturers board decided to discontinue 
the investment in Secure Device on December, 
13 2016. Until then 67 patients were enrolled into 
the trial and all follow-up visits were performed. 
Results
The average age of enrolled patients was 
64.8 ± 15.6 years with an average body mass index 
of 28. Final activation of the Secure Device was 
performed in 63 cases. In 4 cases the device was 
installed but due to user error it was not activated. 
In these cases, manual compression was applied 
with no clinical disadvantage. Patient characteris-
tics are listed in Table 1. 
Time to hemostasis
Time to haemostasis (primary performance 
endpoint) was statistically evaluated in 51 subjects. 
The mean TTH was 4:30 ± 2:15 min in the over-
all observational group with a maximum time of 
13:00 min and a minimum time of 2:00 min. Eleven 
of the subjects undergoing statistical analysis re-
garding TTH received anticoagulation medications 
(all unfractionated heparin; 70 IU/kg). In this sub-
population, TTH was 4:53 ± 1:43 min. TTH was 
not documented in 12 patients in which a Cathofix® 
compression system was applied if TTH was not 
achieved after > 5 min. One of these patients had 
a haematoma prior to the closing procedure. In 
11 patients hemostasis was not primarily reached 
within 3–5 min and the physician decided to apply 
a compression assist system (Femostop®). In these 
cases TTH was not acquired.
Access site complication rate
Two out of 63 (3.2%) individuals experienced 
access site associated complications (primary 
safety endpoint). A palpable haematoma of > 5 cm 
was the only complication in these 2 subjects. In 
terms of severity, both hematomas were catego-
rized as mild since they were only superficial but 
were neither indurated nor visibly swollen. By the 
30 day follow-up, both hematomas had completely 
resolved. Since there were only 63 patients actively 
treated with the device, instead of the 123 subjects 
originally planned for according to the statistical 
sample size calculation, the confidence interval of 
the results was larger than expected.  
Device malfunction rate
Sixty-nine devices were used in 63 patients. 
Two devices had malfunctions (secondary end-
point) that hindered activation of the Secure De-
vice itself. In 14 devices there was either major 
(activation of the device) or minor (artery locator 
protruding) problems during the vascular closing 
procedure, representing a 20.3% malfunction rate. 
Additionally, another 8.7% of the Secure Device 
applications failed due to user errors and device 
misuse. In these cases, either parts of the closing 
procedure or the whole procedure failed. In 1 case 
the missing fixation of the artery locator during 
insertion of the device did not work, and made it 
necessary to also change the system with the de-
ployed artery locator. In some cases an incomplete 
artery locator retraction at the end of the closing 
procedure hindered complete vascular occlusion, 
at which point manual compression was applied. 
Table 1. Clinical characteristics of patients  
included in the study.
Basic characteristics
Patients enrolled 67
Mean age 64.8 ± 15.6
Body mass index 28.2 ± 4.2
Female 19.4%
Intervention 13
Blood pressure [mmHg] 136.5 ± 25.6 / 73.7 ± 11.7
Heart rate [/min] 78.5 ± 11.7
Concommitend medication
ACE-I 10.4%
Beta-blocker 58.2%
Statin 56.7%
Aspirin 64.2%
Anticoagulant 29.9%
P2Y12 inhibitor 23.9%
Heparin 17.9%
Baseline und follow-up lab
Hemoglobin [g/dL] 14.0 ± 1.6
Platelet count [109/L] 207.5 ± 71.2
INR 1.1 (0.85–1.46)
PTT [s] 33.3 ± 4.9
FU hemoglobin [g/dL] 13.3 ± 1.8
FU PLTC [109/L] 234.6 ± 88.1
ACE-I — angiotensin converting enzyme inhibitor; FU — follow-up; 
INR — international normalized ratio; PTT — partial thromboplastin 
time
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Adverse events and severe adverse events
In addition to main access site complication 
rate, additional adverse events as secondary end-
point were analyzed. The most frequent adverse 
events observed were small hematomas. All small 
hematomas were totally resolved within a short 
time and not detected 30 days after the procedure. 
One patient experienced a decrease in blood pres-
sure, local infection (elevated C-reactive protein, 
inconspicuous access site, normal chest X-ray and 
unremarkable urine test) and developed bruising. 
An acute allergic reaction to the contrast agent 
used was investigated in 2 patients and an initial 
manifestation of diabetes was detected in another 
patient. The only reported severe adverse event 
was an unexpected ST-segment elevation myocar-
dial infarction with stent thrombosis after percu-
taneous coronary intervention (PCI), 10 min after 
the closing procedure was completed, which was 
then followed by a second PCI. 
Time to ambulation
The time between Secure Device System 
activation and patient ambulation was assessed. 
Mean time to ambulation was 8:04 ± 6:32 h. In the 
subgroup of patients who received anticoagulants, 
the mean time to ambulation was 12:45 ± 8:54 h. 
Discussion
This study was initiated to investigate the 
safety and efficacy performance of the Secure 
Device System in clinical routine. While manual 
compression is still the gold standard following 
femoral access vascular intervention, vascular 
closure devices have been found to be safe and as-
sociated with less complications in femoral access 
after coronary angiography [6]. Nevertheless, the 
incidence of complications such as hematomas and 
pseudoaneurysms are often discussed with con-
troversy [7]. Relevant complications include groin 
hematomas, bleeding, arteriovenous fistulas and 
pseudoaneurysms developing at the puncture site 
as shown at meta-analysis level. In a PCI setting 
the rate of complications were higher compared 
to diagnostic catheters [8]. More recent data on 
a large cohort of patients investigated intravascu-
lar and extravascular devices compared to manual 
compression. Vascular closure devices showed 
non-inferiority to manual compression in terms 
of vascular access site complications [5]. Compa-
rable results were found with the polymer disc 
based device FemoSeal®, which accomplished faster 
haemostasis with less hematoma formation [6]. 
Suture based closure device and plug based devices, 
regardless of whether they use metal or collagen, ul-
timately leave foreign materials either directly in the 
arterial wall or within the surrounding tissue [5, 9].
Foreign materials may be a problem for 
a patient in long-term if re-puncture is necessary 
or potentially a source for local reactions in the 
arterial wall or the adventitial surrounding. In 
a small number of patients, the presence of a foreign 
material could lead to limb ischemia. Although 
interventional treatment of limb ischemia seems 
feasible [10], these are major adverse events. In 
clinical practice, repetitive use of devices at the 
same puncture site is avoided. Since there is no 
human data regarding fibrosis at the site of punc-
ture, investigating the local effects of collagen 
based devices has been limited to animal models. 
In tissue samples and histological analysis of the 
collagen plug vessel narrowing and peri-adventitial 
inflammation inducing extravascular scarring was 
found in a dog model [11]. A recent trial in minipigs 
also described vessel stenosis influencing blood 
flow and histological alterations following closure 
using collagen plugs [12].
Research into active vascular closure devices 
that do not leave foreign materials at the puncture 
site is a growing field. The idea of using thermal en-
ergy to achieve arterial access occlusion is becom-
ing a focus. The pathophysiological mechanism of 
thermal occlusion is the result of the local collagen 
shrinkage outside the vessel and local swelling to 
achieve hemostasis [4]. In this small trial, TTH was 
accomplished after 3 min for diagnostic procedures 
and 4 min for interventional catheterization, and 
no severe adverse events were reported.
In one fifth of the device applications, either 
device activation issues or intra-procedural obsta-
cles resulted in changing the device or switching 
to manual compression. Although malfunctions are 
a common problem in vascular closure devices, 
malfunction rates are highly variable depending 
on the device. The StarClose System, a clip based 
device, has a malfunction rate around 1.1%. An-
gioSeal, a well-established collagen plug induced 
vascular closure device, has been found to have 
malfunction rates up to 10% [13, 14]. The majority 
of the device malfunctions occurred at the begin-
ning of the Secure Device activation, so the device 
was able to be changed and did not influence the 
study procedure. None of the device malfunctions 
were related to patient safety.
The average time to hemostasis in the 54 as-
sessed individuals was slightly above 4 min (2 to 
13 min). The complication rate was low for the 
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Secure Device. Clinical follow-up included physi-
cal examination focussing on the access site. No 
duplex was performed unless auscultation or 
palpation were suspicious for an access site com-
plication. Although physical examinations were all 
performed by experienced clinicians it cannot be 
ruled out that a vascular complication only detect-
able by duplex might have been present. However, 
there was no case of an access site related problem 
within the 30 day follow-up, supporting the idea 
that no additional complications developed. The 
only access site associated complication was the 
occurrence of a hematoma larger than 5 cm. In 
2 cases, a relevant hematoma was detected. The 
device was successfully applied in both cases and 
time to hemostasis was obtained in 5 and 6 min 
after device activation, respectively. 
Although the study was terminated after 
only 63 patients with active use of the Secure 
Device, since the measured proportion of access 
site complications was 3.2%, lower than the ex-
pected proportion of up to 5%, the data from the 
63 patients was sufficient to reject the predefined 
null-hypothesis. However, it should be noted that 
baseline characteristics between this trial and the 
ISAR-CLOSURE trial revealed some differences. 
The percentage of female participants as well as 
average age was higher in the ISAR CLOSURE trial 
increasing the risk for bleeding whereas body mass 
index was higher in the present study. With respect 
to anticoagulation and antithrombotic medication 
there was comparable use of acetylsalicylic acid in 
both trials (~2/3 of all patients) but P2Y12 inhibi-
tors were used more often in the ISAR-CLOSURE 
trial whereas anticoagulation was more frequent in 
the present trial. An important difference regard-
ing the follow-up of the patients is the systematic 
duplex-sonographic follow-up in ISAR-CLOSURE. 
Although it cannot be ruled out that routine du-
plex was more sensitive to detect access site 
complications (predefined complications were the 
composite of hematoma ≥ 5 cm, pseudoaneurysm, 
arterio-venous fistula, access-site-related major 
bleeding, acute ipsilateral leg ischemia, need for 
vascular surgical/interventional treatment or local 
infection) these should have been detected with 
this two step approach. 
It is known that minor vascular events have 
been found to occur frequently with different de-
vices [15]. Besides the two primary safety endpoint 
events of groin hematomas > 5 cm, 9 small local 
hematomas were reported as adverse events. 
Three other anticipated adverse events were re-
ported. Either blood pressure decrease, infection 
or bruising was observed in 3 different patients. 
All of the investigated events might be potentially 
device related, although they were evaluated only 
descriptively in this trial. 
In the subgroup of patients that received man-
ual compression after Secure Device activation, as 
decided by the physician, the time to hemostasis 
was not evaluated. 
The present study investigated a moderate 
rate of user failure, although extensive training 
had been performed. In prior clinical experience 
with the application system, especially the artery 
locator and the handling of the Secure Device itself, 
it requires additional practice in order to become 
adept. Compared to other vascular closure devices, 
further development of the device might increase 
user friendly application. 
Conclusions
Vascular occlusion devices are commonly used 
for femoral access catheterization. 
The new Secure Device uses thermal energy and 
has been found to be feasible in both diagnostic and 
interventional cardiac catheterization in this small 
and prematurely concluded trial. In comparison to 
established devices, it has the advantage of leaving 
no foreign material in the body following closure. 
Based on the limited data available it seems to 
be non-inferior to other closure devices in terms 
of safety.
However, the rate of malfunctions was still 
significant and requests further development of 
the technique. 
Further clinical investigation will be needed 
regarding the Secure Device thermal vascular 
closure technique in larger patient populations.
Funding: The study was funded by Calore Medical 
Ltd., 14 HaIlan st., Or Akiva, Israel, 30600.
Conflict of interest: Michael Sacherer, Olev Luha 
and Robert Zweiker were sub-investigators, Karin 
Brandner was study nurse and Dirk von Lewinski 
was principle investigator in this funded trial.
References
1. Walter J, Vogl M, Holderried M, et al. Manual Compression 
versus Vascular Closing Device for Closing Access Puncture 
Site in Femoral Left-Heart Catheterization and Percutaneous 
Coronary Interventions: A Retrospective Cross-Sectional Com-
parison of Costs and Effects in Inpatient Care. Value Health. 
2017; 20(6): 769–776, doi: 10.1016/j.jval.2016.05.004, indexed in 
Pubmed: 28577694.
www.cardiologyjournal.org 239
Michael Sacherer et al., Thermic sealing in femoral catheterisation: First experience with the Secure Device
2. Hon LQ, Ganeshan A, Thomas SM, et al. An overview of vas-
cular closure devices: what every radiologist should know. Eur 
J Radiol. 2010; 73(1): 181–190, doi: 10.1016/j.ejrad.2008.09.023, 
indexed in Pubmed: 19041208.
3. Krishnasamy VP, Hagar MJ, Scher DJ, et al. Vascular clo-
sure devices: technical tips, complications, and management. 
Tech Vasc Interv Radiol. 2015; 18(2): 100–112, doi:  10.1053/j.
tvir.2015.04.008, indexed in Pubmed: 26070622.
4. Davidson LJ, Luna J, Virmani R, et al. First human experience of 
thermal arterial closure. Catheter Cardiovasc Interv. 2014; 84(1): 
30–36, doi: 10.1002/ccd.25152, indexed in Pubmed: 23934606.
5. Schulz-Schüpke S, Helde S, Gewalt S, et al. Comparison of 
vascular closure devices vs manual compression after femoral 
artery puncture: the ISAR-CLOSURE randomized clinical trial. 
JAMA. 2014; 312(19): 1981–1987, doi: 10.1001/jama.2014.15305, 
indexed in Pubmed: 25399273.
6. Holm NR, Sindberg B, Schou M, et al. Randomised comparison 
of manual compression and FemoSeal™ vascular closure device 
for closure after femoral artery access coronary angiography: 
the CLOSure dEvices Used in everyday Practice (CLOSE-UP) 
study. EuroIntervention. 2014; 10(2): 183–190, doi: 10.4244/EI-
JV10I2A31, indexed in Pubmed: 24603054.
7. Koreny M, Riedmüller E, Nikfardjam M, et al. Arterial puncture 
closing devices compared with standard manual compression af-
ter cardiac catheterization: systematic review and meta-analysis. 
JAMA. 2004; 291(3): 350–357, doi: 10.1001/jama.291.3.350, in-
dexed in Pubmed: 14734598.
8. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications as-
sociated with arteriotomy closure devices in patients undergoing 
percutaneous coronary procedures: a meta-analysis. J Am Coll 
Cardiol. 2004; 44(6): 1200–1209, doi: 10.1016/j.jacc.2004.06.048, 
indexed in Pubmed: 15364320.
9. Martin JL, Pratsos A, Magargee E, et al. A randomized trial 
comparing compression, Perclose Proglide and Angio-Seal VIP 
for arterial closure following percutaneous coronary interven-
tion: the CAP trial. Catheter Cardiovasc Interv. 2008; 71(1): 1–5, 
doi: 10.1002/ccd.21333, indexed in Pubmed: 18098171.
10. Dong H, Peng M, Jiang X, et al. Endovascular therapy for Angio-
seal-related acute limb ischemia: Perioperative and long-term 
results. Catheter Cardiovasc Interv. 2017; 89(S1): 609–615, 
doi: 10.1002/ccd.26936, indexed in Pubmed: 28191744.
11. Gargiulo NJ, Veith FJ, Ohki T, et al. Histologic and duplex compar-
ison of the perclose and angio-seal percutaneous closure devices. 
Vascular. 2007; 15(1): 24–29, doi: 10.2310/6670.2007.00004, in-
dexed in Pubmed: 17382051.
12. Kabelitz L, Nonn A, Nolte KW, et al. Long term outcome after 
application of the angio-seal vascular closure device in mini-
pigs. PLoS One. 2016; 11(9): e0163878, doi:  10.1371/journal.
pone.0163878, indexed in Pubmed: 27682594.
13. Spiliopoulos S, Katsanos K, Karnabatidis D, et al. Safety and 
efficacy of the StarClose vascular closure device in more than 
1000 consecutive peripheral angioplasty procedures. J Endovasc 
Ther. 2011; 18(3): 435–443, doi: 10.1583/10-3277.1, indexed in 
Pubmed: 21679086.
14. Minko P, Katoh M, Gräber S, et al. Obesity: an independent risk 
factor for insufficient hemostasis using the AngioSeal vascular 
closure device after antegrade puncture. Cardiovasc Intervent 
Radiol. 2012; 35(4): 775–778, doi:  10.1007/s00270-011-0230-y, 
indexed in Pubmed: 21792734.
15. Schmelter C, Liebl A, Poullos N, et al. Suitability of Exoseal 
vascular closure device for antegrade femoral artery puncture 
site closure. Cardiovasc Intervent Radiol. 2013; 36(3): 659– 
–668, doi:  10.1007/s00270-012-0501-2, indexed in Pubmed: 
23070109.
240 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 3
